Risk assessment on-a-chip: a cell-based microfluidic device for immunotoxicity screening.

Arianna Oddo1,2, Mariana Morozesk1,3, Enzo Lombi4

  • 1Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University Parkville Victoria 3052 Australia nicolas.voelcker@monash.edu tommy.tong@monash.edu.

Nanoscale Advances
|September 22, 2022
PubMed
Summary

This study developed a microfluidic device to test nanoparticle toxicity on immune cells. Flow conditions significantly increased silver nanoparticle toxicity, suggesting static tests may underestimate nanomaterial risks.

Related Concept Videos